Mechelen, Belgium; 23 November 2018, 22.01 CET; regulated information - Galapagos NV (Euronext & NASDAQ:
GLPG) announces a share capital increase arising from warrant exercises.
Galapagos issued 30,800 new ordinary shares on 23 November 2018, for a total capital increase
(including issuance premium) of €381,865.00.
Pursuant to the warrant exercise program of Galapagos' executive committee, executive committee members
automatically are committed to exercise a minimum number of warrants, subject to certain conditions. In accordance with the rules
of this program, CEO Onno van de Stolpe exercised 15,000 warrants. Three other executive committee members exercised an aggregate
number of 15,000 warrants.
In accordance with Belgian transparency legislation[1], Galapagos notes that its total share capital
currently amounts to €294,599,712.11, the total number of securities conferring voting rights is 54,465,421, which is also the
total number of voting rights (the "denominator"), and all securities conferring voting rights and all voting rights are of the
same category. The total number of rights (warrants) to subscribe to not yet issued securities conferring voting rights is
4,629,282 which equals the total number of voting rights that may result from the exercise of these warrants. Galapagos does not
have any convertible bonds or shares without voting rights outstanding.
About Galapagos
Galapagos (Euronext & NASDAQ: GLPG) is a clinical-stage biotechnology company specialized in the discovery and development of small
molecule medicines with novel modes of action. Galapagos' pipeline comprises Phase 3 through to discovery programs in inflammation,
fibrosis, osteoarthritis and other indications. Our target discovery platform has delivered three novel mechanisms showing
promising patient results in, respectively, inflammatory diseases, idiopathic pulmonary fibrosis and atopic dermatitis. Galapagos
is focused on the development and commercialization of novel medicines that will improve people's lives. The Galapagos group,
including fee-for-service subsidiary Fidelta, has approximately 700 employees, operating from its Mechelen, Belgium headquarters
and facilities in the Netherlands, France, Switzerland, the US and Croatia. More information at www.glpg.com.
Contacts
Investors:
Elizabeth Goodwin
VP IR & Corporate Communications
+1 781 460 1784
Sofie Van Gijsel
Director IR
+32 485 19 14 15
ir@glpg.com
Media:
Evelyn Fox
Director Communications
+31 6 53 591 999
communications@glpg.com
Forward-looking statements
This release may contain forward-looking statements. Such forward-looking statements are not guarantees of future results. These
forward-looking statements speak only as of the date of publication of this document. Galapagos expressly disclaims any obligation
to update any forward-looking statements in this document, unless specifically required by law or regulation.
[1] Belgian Act of 2 May 2007 on the disclosure of major shareholdings in issuers whose shares are
admitted to trading on a regulated market
